GlobeNewswire: Amarantus BioScience Holdings, Inc. Contains the last 10 of 214 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T01:07:28ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/06/1981060/0/en/Amarantus-Announces-Subsidiary-MANF-Therapeutics-Enters-Into-Material-Transfer-Agreement-with-Dyadic-International.html?f=22&fvtc=4&fvtv=19834Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International2020-02-06T13:11:12Z<![CDATA[New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics, as well as CBD Wellness through its subsidiaries, today announced that its wholly-owned subsidiary MANF Therapeutics has entered into a material transfer agreement (MTA) with Dyadic International, Inc. (Nasdaq:DYAI , or Dyadic) to transfer existing batches of mesencephalic astrocyte-derived neurotrophic factor (MANF) therapeutic protein previously manufactured by third parties in baculovirus and CHO to Dyadic to assist in the evaluation of the potential of Dyadic’s proprietary C1 biologics production platform to manufacture MANF for clinical and commercial use. C1, based on the fungus Myceliophthora thermophila, is a microorganism which enables the development and large scale manufacture of low-cost biologics, and has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologics, including therapeutic proteins such as MANF.]]>https://www.globenewswire.com/news-release/2020/02/04/1979591/0/en/Amarantus-Releases-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=19834Amarantus Releases Letter to Shareholders2020-02-04T14:54:00Z<![CDATA[New York, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics, as well as CBD Wellness through its subsidiaries, today released a letter to shareholders:]]>https://www.globenewswire.com/news-release/2020/01/30/1977586/0/en/Amarantus-Acquires-Majority-Interest-in-CBD-Wellness-Company-Hempori.html?f=22&fvtc=4&fvtv=19834Amarantus Acquires Majority Interest in CBD Wellness Company Hempori2020-01-30T14:05:42Z<![CDATA[New York, NY and Dallas, TX , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics through its subsidiaries, today announced that it has acquired a controlling interest in Hempori, Inc., a CBD wellness retailer in Dallas, TX with 2 stores and a growing physical and online presence. Concurrent with this announcement, Hempori has placed an initial purchase order for hemp smokes from Emerald Organic Products, Inc. (OTCPK: EMOR), an Amarantus partner. Amarantus intends to evaluate a smoking cessation program, with an initial focus of getting feedback on the hemp smokable products from customers who are actively seeking to reduce, or cease, chronic use of cigarettes and/or e-cigarettes]]>https://www.globenewswire.com/news-release/2020/01/02/1965673/0/en/Amarantus-Completes-Sublicense-of-ESS-MANF-and-PhenoGuard-to-Emerald-Organic-Products.html?f=22&fvtc=4&fvtv=19834Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products2020-01-02T13:14:15Z<![CDATA[New York, NY, Jan. 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics through its subsidiaries, today announced that it has completed an exclusive worldwide sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products (OTCPK: EMOR, or “Emerald”), a diversified cannabidiol (“CBD”)-focused health sciences company. Emerald now has development rights to Engineered Skin Substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard for all applications. RHK Capital, a boutique Connecticut-based investment bank, advised Emerald on the transaction.]]>https://www.globenewswire.com/news-release/2019/12/09/1957861/0/en/Amarantus-to-Present-at-12th-Annual-LD-Micro-Main-Event.html?f=22&fvtc=4&fvtv=19834Amarantus to Present at 12th Annual LD Micro Main Event2019-12-09T13:00:00Z<![CDATA[NEW YORK, NY, Dec. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, and diagnostics through its subsidiaries, today announced that its President & CEO Gerald Commissiong will be presenting a corporate overview at the 12th Annual LD Micro Main Event on December 10th, 2019 at 4:00 p.m. PST. Management will be available to meet with interested parties 1 on 1 throughout both events.]]>https://www.globenewswire.com/news-release/2019/12/04/1956095/0/en/Amarantus-Subsidiary-Elto-Pharma-Receives-Notice-of-Allowance-Covering-Use-of-Eltoprazine-Combined-with-CBD-to-Treat-Parkinson-s-Disease.html?f=22&fvtc=4&fvtv=19834Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease2019-12-04T12:36:36Z<![CDATA[· Patent extends patent coverage for eltoprazine to 2034]]>https://www.globenewswire.com/news-release/2019/11/21/1950738/0/en/Amarantus-Announces-Issuance-of-Chinese-Patent-Covering-the-Use-of-MANF-and-CDNF-in-Retinal-Disorders-for-Subsidiary-MANF-Therapeutics.html?f=22&fvtc=4&fvtv=19834Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics2019-11-21T13:00:00Z<![CDATA[Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa]]>https://www.globenewswire.com/news-release/2019/11/18/1948708/0/en/Amarantus-Provides-Recapitalization-Update-to-Shareholders.html?f=22&fvtc=4&fvtv=19834Amarantus Provides Recapitalization Update to Shareholders2019-11-18T13:30:00Z<![CDATA[New York, NY, Nov. 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today released a letter to its shareholders following the announcement of the binding term sheet to license the Company’s therapeutics subsidiaries’ technologies to Emerald Organic Products, an emerging CBD-focused health sciences company, and other recent events:]]>https://www.globenewswire.com/news-release/2019/10/24/1935060/0/en/Amarantus-Enters-Into-Agreement-to-License-Diverse-Therapeutics-Portfolio-to-CBD-focused-Emerald-Organic-Products.html?f=22&fvtc=4&fvtv=19834Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products2019-10-24T13:34:27Z<![CDATA[NEW YORK, NY, Oct. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc. (OTCPK: EMOR) (“Emerald” or EMOR), a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels. Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard. Key Amarantus team members will incubate Emerald’s emerging life sciences unit. The transaction is subject to customary closing conditions and the consent of certain Amarantus stakeholders.]]>https://www.globenewswire.com/news-release/2019/06/25/1873704/0/en/Amarantus-Enters-into-Letter-of-Intent-with-The-Alchemists-Kitchen-to-Establish-Joint-Venture-for-Research-and-Commercialization-of-Hemp-and-Herbal-Smokables-for-Addiction-Treatmen.html?f=22&fvtc=4&fvtv=19834Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation2019-06-25T12:00:00Z<![CDATA[NEW YORK, NY, June 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it has entered into a Letter of Intent (‘LOI’) with The Alchemist’s Kitchen, a plant-based wellness company marketing the Plant Alchemy brand of health and wellness products, to establish a joint venture for commercialization of hemp based herbal smokable products ‘Herbal Smokes’ in addition to conducting research for cannabinoid derived addiction treatment, including smoking cessation (tobacco and vaping-based/e-cigarette), and other indications such as insomnia (the ‘Evolver Herbal Smokes’ or the ‘JV’). The initial equity ownership of Evolver Herbal Smokes will be 19.99% for Amarantus, and 80.01% for The Alchemist’s Kitchen and/or its affiliates. Amarantus will have the right to acquire the remaining 80.01% equity of Evolver Herbal Smokes in conjunction with the listing of its common shares onto a national stock exchange.]]>